IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the commencement of a proposed public offering of its ordinary shares. All of the securities to be sold in the offering are to be offered by IceCure. The proposed public offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Will iPhone 15 Pro Max Disappoint Fans With Familiar Camera? What New Leaks Suggest
Apple Inc. (NASDAQ:AAPL) enthusiasts eagerly waiting for the release of the iPhone 15 Pro Max might be in for a disappointment,…